WILMINGTON, N.C., Dec. 21, 2015 /PRNewswire/ -- AAIPharma Services Corp./Cambridge Major Laboratories, Inc. (AAI/CML), a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, today announces additional capabilities and capacity for oral solid manufacturing in its Wilmington, NC facility. These investments have been driven by the significant growth in our drug product portfolio, particularly for orphan drugs and rare disease therapies.
Some of the recent additions to our oral solid capabilities include precision coating for our fluid bed dryer (GEA/MP-4), which allows for bottom spray coating for enteric release products. Also, it allows top spray granulatation and drying for materials from the (GEA/PMA-400) high shear mixer. The additional bottom spray coating capability was introduced along with the extruder spheronizer (GEA NICAS450/NICA140). Lastly, a Bosch KKE 1700 capsule checkweighter was added to increase the encapsulation capabilities. With the addition of this equipment and a second manufacturing shift, the solid dosage capacity has increased by approximately 35%.
"Our facility upgrades in Wilmington for Drug Product complement the overall progress of our laboratory and headquarters expansions. We are excited to have this top of the line equipment and added capability for specialized areas of drug product development and manufacturing," stated Ted Dolan, Chief Operating Officer.
These new capabilities complement our existing specialties which include Minitabs, Pediatric Sprinkles, Chewable Products, Sublingual Tablets, Orally Disintegrating Tablets, Extrusion Granules, and Extrusion Spheronization. AAI/CML also has the capability to manufacture potent drugs, controlled substances, and moisture/oxygen sensitive drugs. AAI/CML will continue to invest in unique capabilties and facility upgrades as its portfolio expands.
About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.
SOURCE AAIPharma Services Corp./Cambridge Major Laboratories, Inc.